fig6
![Engineered induced-pluripotent stem cell derived monocyte extracellular vesicles alter inflammation in HIV humanized mice](https://image.oaes.cc/ca6b0ed4-fdfd-4075-85e4-0ff7e0b5aa54/4822.fig.6.jpg)
Figure 6. PBMC profile of iPSC-monocyte EV (mEV) treated HIV+ BLT mice. (A) %CD14+ of CD3-CD19-, classical monocytes (CD16-CD14++), intermediate monocytes (CD16+CD14++) and non-classical monocytes (CD16++CD14+) (B) %CCR5 expression of overall monocytes (CD14+CD3-CD19-), classical monocytes (CD16-CD14++), intermediate monocytes (CD16+CD14++) and non-classical monocytes (CD16++CD14+) (C) %CCR5 and %CD16 of macrophages including M1 macrophages (CD163-CD11b+CD3-CD19-) and M2 macrophages (CD163+CD11b+CD3-CD19-) (D) %CCR5 and %HLA-DR of CD4+ or CD8+ T cells.